Literature DB >> 27051388

If Chemotherapy Is Indicated, Give the Optimal Regimen!

Volker Möbus1.   

Abstract

Year:  2016        PMID： 27051388      PMCID： PMC4813648          DOI： 10.1159/000444512

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  6 in total

1.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Authors:  Lucia Del Mastro; Sabino De Placido; Paolo Bruzzi; Michele De Laurentiis; Corrado Boni; Giovanna Cavazzini; Antonio Durando; Anna Turletti; Cecilia Nisticò; Enrichetta Valle; Ornella Garrone; Fabio Puglisi; Filippo Montemurro; Sandro Barni; Andrea Ardizzoni; Teresa Gamucci; Giuseppe Colantuoni; Mario Giuliano; Adriano Gravina; Paola Papaldo; Claudia Bighin; Giancarlo Bisagni; Valeria Forestieri; Francesco Cognetti
Journal:  Lancet       Date:  2015-03-02       Impact factor: 79.321

2.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

3.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

4.  Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Authors:  U Nitz; O Gluz; J Huober; H H Kreipe; R E Kates; A Hartmann; R Erber; Z Moustafa; M Scholz; B Lisboa; S Mohrmann; V Möbus; D Augustin; G Hoffmann; E Weiss; S Böhmer; R Kreienberg; A Du Bois; D Sattler; C Thomssen; M Kiechle; F Jänicke; D Wallwiener; N Harbeck; W Kuhn
Journal:  Ann Oncol       Date:  2014-05-14       Impact factor: 32.976

Review 5.  Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Luisa Bonilla; Irit Ben-Aharon; Liat Vidal; Anat Gafter-Gvili; Leonard Leibovici; Salomon M Stemmer
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

6.  WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.

Authors:  Daniel Hofmann; Ulrike Nitz; Oleg Gluz; Ronald E Kates; Timo Schinkoethe; Peter Staib; Nadia Harbeck
Journal:  Trials       Date:  2013-08-19       Impact factor: 2.279
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.